KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $69.7 million.

  • Amneal Pharmaceuticals' Change in Accured Expenses rose 4886.56% to $69.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.0 million, marking a year-over-year decrease of 5372.79%. This contributed to the annual value of $235.1 million for FY2024, which is 34896.24% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Change in Accured Expenses of $69.7 million as of Q3 2025, which was up 4886.56% from $45.6 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Change in Accured Expenses peaked at $322.7 million during Q2 2022, and registered a low of -$150.5 million during Q1 2023.
  • Its 5-year average for Change in Accured Expenses is $11.0 million, with a median of $16.1 million in 2021.
  • Within the past 5 years, the most significant YoY rise in Amneal Pharmaceuticals' Change in Accured Expenses was 190586.74% (2022), while the steepest drop was 82886.49% (2022).
  • Over the past 5 years, Amneal Pharmaceuticals' Change in Accured Expenses (Quarter) stood at -$11.1 million in 2021, then tumbled by 402.74% to -$55.9 million in 2022, then surged by 64.63% to -$19.8 million in 2023, then skyrocketed by 435.29% to $66.3 million in 2024, then rose by 5.27% to $69.7 million in 2025.
  • Its last three reported values are $69.7 million in Q3 2025, $45.6 million for Q2 2025, and -$112.6 million during Q1 2025.